Andere Sprachen Quoin Pharmaceuticals, Ltd.

Aktien

A3EJL7

US74907L3006

QNRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
0,7763 ^USD	+6,34 %		+21,77 %	-84,17 %

15.03.	QUOIN PHARMACEUTICALS, LTD. : Maxim gibt eine Kauf-Bewertung ab	ZM
14.03.	Quoin Pharmaceuticals sucht nach M&A-Möglichkeiten	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024	02.05.
Quoin Pharmaceuticals Seeks M&A Opportunities	14.03.
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	13.03.
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results	13.03.
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET	07.03.
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	06.03.
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	05.03.
Top Midday Decliners	05.03.
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall	05.03.
Top Premarket Decliners	05.03.
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering	05.03.
Top Midday Gainers	04.03.
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	04.03.
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04.03.
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04.03.
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome	15.02.
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08.02.
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08.02.
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP	25.01.
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Quoin Pharmaceuticals, Ltd.

Aktien

A3EJL7

US74907L3006

QNRX

Andere Sprachen

Filter